Latest pharma news
Jun 02, 2026
Hanmi Pharmaceutical and Eli Lilly and Company Join Forces to Advance Sonefpeglutide Development; Johnson & Johnson’s ERLEADA Achieves Positive Phase 3 Outcomes; Revolution Medicines Unveils Landmark Phase 3 RASolute 302 Data Demonstrating Strong Efficacy of Daraxonrasib in Metastatic Pancreatic Cancer; Pfizer’s BRAFTOVI Treatment Advances Outcomes by Nearly Doubling Progression-Free Survival in mCRC; Imfinzi Sets a New Standard with US Approval of the Only Immunotherapy Combination for BCG-Naïve High-Risk Bladder Cancer
Hanmi Pharmaceutical Secures Licensing Agreement with Eli Lilly and Company for Sonefpeglutide Hanmi Pharmaceutical announced a licensing agreement with Eli Lilly and Company covering the development, manufacturing, and commercialization of sonefpeglutide (LAPSGLP-2 analog), Hanmi’s investigational biologi...
Read More...
May 26, 2026
US Greenlight for Datroway Marks First TROP2 ADC Approval in Frontline mTNBC Beyond PD-1/PD-L1 Candidates; Gilead’s Hepcludex Achieves Historic FDA Approval Milestone in Chronic HDV; Biogen and Denali Therapeutics Report Progress in Phase 2b Evaluation of BIIB122 for Parkinson’s Disease; Eli Lilly and Company Spotlights Foundayo’s Late-Stage Success in Obesity Studies; BioMarin Shares Successful Phase 3 Study Outcomes for VOXZOGO® in Children with Hypochondroplasia
US Approves Datroway as the First TROP2-directed ADC for 1L mTNBC Patients Unsuitable for PD-1/PD-L1 Therapy AstraZeneca and Daiichi Sankyo have secured US approval for Datroway for treating adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor th...
Read More...
May 19, 2026
BAXFENDY Receives US Approval for Adult Hypertension as a First-in-Class Aldosterone Synthase Inhibitor; Regeneron Pharmaceuticals Shares New Developments in Phase 3 Melanoma Study of Fianlimab Combination; ENHERTU Gains Two New US Indications in HER2-positive Early Breast Cancer; REGENXBIO Reveals Positive Pivotal Trial Results for Duchenne Gene Therapy RGX-202; BeOne Medicines Gains FDA Approval for BEQALZI™ in R/R Mantle Cell Lymphoma
BAXFENDY Becomes the First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension AstraZeneca’s BAXFENDY (baxdrostat) has received US approval as the first aldosterone synthase inhibitor (ASI) for treating hypertension in adults whose blood pressure remains uncontrolled despite the use of other...
Read More...
May 12, 2026
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China; Artiva Announces Strong Early AlloNK® Results and FDA Alignment for Pivotal Rheumatoid Arthritis Trial in 2026; FDA Reviews LEQEMBI IQLIK Subcutaneous Starting Dose Under Priority Review Pathway; ParcelBio Announces Programmable mRNA Platform Amid $13M Capital Infusion; Entrada Therapeutics Reports Promising Topline Efficacy and Safety Results for ENTR-601-44 in Duchenne Muscular Dystrophy
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China GSK plc revealed an exclusive strategic partnership with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aimed at supporting the launch and expansion of bepir...
Read More...
May 05, 2026
UCB to Acquire Candid Therapeutics; Pfizer’s ELREXFIO Sets New Benchmark in PFS for Hard-to-Treat Multiple Myeloma Patients; Axsome Therapeutics Wins FDA Approval for AUVELITY to Address Alzheimer’s Agitation; FDA Advisory Panel Backs Truqap for PTEN-Deficient mHSPC; Bepirovirsen Receives FDA Priority Review Alongside Breakthrough Therapy Tag
UCB Bets on Candid Therapeutics to Boost Immunology Pipeline with T-cell Engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics, strengthening its immunology pipeline and advancing its capabilities in next-generation biologics, particularly T-cell engagers (TCEs). The deal aligns wit...
Read More...
Apr 28, 2026
Eli Lilly and Company to Acquire Ajax Therapeutics; Sun Pharma Moves to Acquire Organon in Definitive Agreement; European Commission Approves Novartis RHAPSIDO as First Oral Targeted Therapy for Chronic Spontaneous Urticaria; Tovecimig Delivers Significant Clinical Benefit in COMPANION-002 Phase 2/3 Trial for Biliary Tract Cancer; Arrowhead Pharmaceuticals Receives CHMP Backing for REDEMPLO Approval in Europe for Familial Chylomicronemia Syndrome
Eli Lilly and Company Signs Deal to Acquire Ajax Therapeutics Eli Lilly and Company has entered into a definitive agreement to acquire Ajax Therapeutics, Inc., a biotechnology firm specializing in next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs). The deal is structured with a total potentia...
Read More...
Apr 21, 2026
Novo Nordisk Reports Positive Phase 3 Results for Etavopivat in Sickle Cell Disease; UCB to Buy Neurona Therapeutics; KEYTRUDA Regimens Secure FDA Priority Review in Muscle-Invasive Bladder Cancer; Savara Announces FDA Review Extension for Molgramostim in Autoimmune PAP; Terremoto Biosciences Completes $108 Million Series C Financing to Expand AKT1 Inhibitor Development
Novo Nordisk’s Etavopivat Meets Phase 3 Endpoints in Sickle Cell Disease Novo Nordisk announced topline findings from HIBISCUS, a pivotal Phase 3 study evaluating once-daily oral etavopivat in adults and adolescents living with Sickle Cell Disease. The trial met both co-primary endpoints, with etavopivat showing...
Read More...
Apr 14, 2026
IDEAYA and Servier Reports Successful Uveal Melanoma Trial; SynOx Therapeutics Highlights Positive Phase 3 TANGENT Topline Data; Regeneron and Telix Ink Strategic Radiopharma Deal; GSK Shares Promising Clinical Data on B7-H4-Targeted ADC; Replimune’s RP1 Hits Regulatory Hurdle with FDA Complete Response Letter
IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients ...
Read More...
Apr 07, 2026
Neurocrine Signs Deal to Acquire Soleno Therapeutics; AstraZeneca Shares Favorable Results from EMERALD-3 Study in Liver Cancer; Immunovant Presents Phase 3 Clinical Data for Batoclimab in TED; Alto Neuroscience Shares Topline Findings from Phase 2 ALTO-101 Study and Pipeline Updates; ORIC Positions Rinzimetostat for Phase 3 Success with Optimized Dosing Strategy
Neurocrine Announces Acquisition of Soleno Therapeutics to Broaden Rare Disease Portfolio Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics in a transaction valued at approximately $2.9 billion, marking a significant strategic expansion into the rare disease and metabo...
Read More...
Mar 31, 2026
Tanabe Pharma Shares Encouraging Phase 3 Data for Dersimelagon in Rare Photodermatoses; Biogen’s Litifilimab Demonstrates Significant Skin Disease Reduction in Phase 2 CLE Trial; Merck’s WINREVAIR Shows Promising Phase 2 Results in CpcPH-HFpEF Population; AstraZeneca’s Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III COPD Trials; Amgen’s REPATHA Shows Strong Cardiovascular Risk Reduction in High-Risk Patients
Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for Dersimelagon in EPP and XLP Tanabe Pharma Corporation has announced detailed findings from the Phase 3 INSPIRE trial evaluating investigational oral dersimelagon in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
